CTI provides this data for informational and research purposes only. The data is not intended for trading purposes. Neither CTI nor any of its data content providers shall be liable for any errors or delays in the content, or for any actions in reliance thereon. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Please see Terms of Use for this website.

Investor Relations Contacts
Monique Greer
+1 206-272-4343
Laura Villa
+39 02 94751572
+1 206-272-4155 (U.S. only)
Ed Bell
+1 206-272-4345
Recent News
Apr 22, 2014Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014Printer Friendly Version
Mar 05, 2014Cell Therapeutics to Present at the 26th Annual ROTH ConferencePrinter Friendly Version
Mar 04, 2014Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial ResultsPrinter Friendly Version
Mar 03, 2014CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet CountsPrinter Friendly Version
Feb 27, 2014NICE Publishes Final Guidance on PIXUVRI® (pixantrone)Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.